Pipeline
Transforming the treatment of disease with highly selective therapeutic antibodies.
Existing therapeutics indiscriminately kill both healthy and diseased cells
Unlocking killing selectivity through avidity
The biological mechanism that we’ve used to achieve killing selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, our optimised T-cell engagers are able to differentiate between a healthy and diseased cell based on differential TAA expression.
Conventional methods marginally widen therapeutic windows
LabGenius’ approach delivers complete on/off killing selectivity
Modality
Development Stage
Target Selection
Lead Discovery
Lead Optimisation
IND-enabling
Clinical Phase 1
Modality:
Bispecific TCE
For our chosen target, by developing a selectivity-enhanced T-cell engager (TCE), we have an opportunity to be both first-in-modality and best-in-class. In this programme, we’ve used our platform to discover and co-optimise a TCE for enhanced killing selectivity, potency, efficacy and manufacturability. The biological mechanism that we’ve used to achieve killing selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, our optimised TCE is able to differentiate between a healthy and diseased cell based on differential tumour-associated expression.
